Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XAF5 Ointment for Lower Lid Steatoblepharon
NCT02607683Phase 3Completed
- Sponsor
- Topokine Therapeutics
- Start
- Jan 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of XAF5 in Steatoblepharon (3 arms), sponsored by Topokine Therapeutics. Primary endpoint: Lower Eyelid Steatoblepharon Severity at 16 weeks. Started Jan 2016; status: completed.
02
Drugs
XAF5
03
Conditions
Steatoblepharon
Beyond the preview
Go deeper on NCT02607683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607683.